BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Group 1 - Supernus Pharmaceuticals, Inc. shares fell over 13% on February 19, 2025, after the company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo [2] - The outcome of the study was unexpected for investors, given the company's previous optimism regarding the drug's potential [2] - Block & Leviton is investigating Supernus Pharmaceuticals for potential securities law violations related to the company's prior disclosures [4] Group 2 - Investors who purchased Supernus Pharmaceuticals, Inc. common stock and experienced a loss may be eligible to recover those losses, regardless of whether they have sold their investment [3] - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors [7] - The firm encourages individuals with non-public information about Supernus Pharmaceuticals to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]